Mitogen-activated protein kinase pathway in osteosarcoma

Pathology

Volumn 44, Issue 6, 2012, Pages 540-546

  Na, Ki Yong ^a   Kim, Youn Wha ^a   Park, Yong Koo ^a,b  

^a Kyung Hee University College of Medicine   (South Korea)

^b Medical Science and Engineering Research Center for Bioreactions to Reactive Oxygen Species   (South Korea)

Author keywords

ERK; MEK; Osteosarcoma; Raf; Ras

Indexed keywords

EID: 84866902305     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e32835803bc     Document Type: Article

References (29)

1. Bramer JA, van Linge JH, Grimer RJ, et al. Prognostic factors in localized extremity osteosarcoma: a systematic review. Eur J Surg Oncol 2009; 35: 1030-6.
2. Kong C, Hansen MF. Biomarkers in osteosarcoma. Expert Opin Med Diagn 2009; 3: 13-23.
3. Wachtel M, Schafer BW. Targets for cancer therapy in childhood sarcomas. Cancer Treat Rev 2010; 36: 318-27.
4. McCubrey JA, Steelman LS, Chappell WH, et al. Roles of the Raf/MEK/ ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007; 1773: 1263-84.
5. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer 2003; 3: 459-65.
6. Grabocka E, Bar-Sagi D. Raf-1 and squamous cell carcinoma: Rok-ing the boat. Cancer Cell 2009; 16: 85-6.
7. Hagemann C, Gloger J, Anacker J, et al. RAF expression in human astrocytic tumors. Int J Mol Med 2009; 23: 17-31.
8. Blasco RB, Francoz S, Santamaria D, et al. c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. Cancer Cell 2011; 19: 652-63.
9. Ikeda S, Sumii H, Akiyama K, et al. Amplification of both c-myc and c-raf- 1 oncogenes in a human osteosarcoma. Jpn J Cancer Res 1989; 80: 6-9.
10. Pignochino Y, Grignani G, Cavalloni G, et al. Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Mol Cancer 2009; 8: 118.
11. Wolfesberger B, Tonar Z, Gerner W, et al. The tyrosine kinase inhibitor sorafenib decreases cell number and induces apoptosis in a canine osteosarcoma cell line. Res Vet Sci 2010; 88: 94-100.
12. Tsubaki M, Yamazoe Y, Yanae M, et al. Blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathways by statins reduces the expression of bFGF, HGF, and TGF-beta as angiogenic factors in mouse osteosarcoma. Cytokine 2011; 54: 100-7.
13. Abdeen A, Chou AJ, Healey JH, et al. Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma. Cancer 2009; 115: 5243-50.
14. Kim MS, Lee SY, Lee TR, et al. Prognostic nomogram for predicting the 5-year probability of developing metastasis after neo-adjuvant chemotherapy and definitive surgery for AJCC stage II extremity osteosarcoma. Ann Oncol 2009; 20: 955-60.
15. Do SI, Jung WW, Kim HS, et al. The expression of epidermal growth factor receptor and its downstream signaling molecules in osteosarcoma. Int J Oncol 2009; 34: 797-803.
16. Sasaki K, Hitora T, Nakamura O, et al. The role of MAPK pathway in bone and soft tissue tumors. Anticancer Res 2011; 31: 549-53.
17. McPhillips F, Mullen P, Monia BP, et al. Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer. Br J Cancer 2001; 85: 1753-8.
18. Lee SH, Lee JW, Soung YH, et al. Colorectal tumors frequently express phosphorylated mitogen-activated protein kinase. APMIS 2004; 112: 233-8.
19. Liang B,Wang S, Zhu XG, et al. Increased expression of mitogen-activated protein kinase and its upstream regulating signal in human gastric cancer. World J Gastroenterol 2005; 11: 623-8.
20. Milde-Langosch K, Bamberger AM, Rieck G, et al. Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancer. Br J Cancer 2005; 92: 2206-15.
21. Li Q, Yang Z. Expression of phospho-ERK1/2 and PI3-K in benign and malignant gallbladder lesions and its clinical and pathological correlations. J Exp Clin Cancer Res 2009; 28:
22. Chen L, Shi Y, Jiang CY, et al. Expression and prognostic role of pan-Ras, Raf-1, pMEK1 and pERK1/2 in patients with hepatocellular carcinoma. Eur J Surg Oncol 2011; 37: 513-20.
23. Spallarossa P, Altieri P, Garibaldi S, et al. Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in H9c2 cells: The role of MAP kinases and NAD(P)H oxidase. Cardiovasc Res 2006; 69: 736-45.
24. Yu Y, Luk F, Yang JL, et al. Ras/Raf/MEK/ERK pathway is associated with lung metastasis of osteosarcoma in an orthotopic mouse model. Anticancer Res 2011; 31: 1147-52.
25. Shimo T, Matsumura S, Ibaragi S, et al. Specific inhibitor of MEKmediated cross-talk between ERK and p38 MAPK during differentiation of human osteosarcoma cells. J Cell Commun Signal 2007; 1: 103-11.
26. Liu X, Zeng B, Ma J, et al. Comparative proteomic analysis of osteosarcoma cell and human primary cultured osteoblastic cell. Cancer Invest 2009; 27: 345-52.
27. Kawaguchi K, Oda Y, Sakamoto A, et al. Molecular analysis of p53, MDM2, and H-ras genes in osteosarcoma and malignant fibrous histiocytoma of bone in patients older than 40 years. Mod Pathol 2002; 15: 878-88.
28. Yang R, Piperdi S, Gorlick R. Activation of the RAF/mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signalregulated kinase pathway mediates apoptosis induced by chelerythrine in osteosarcoma. Clin Cancer Res 2008; 14: 6396-404.
29. Geryk-Hall M, Yang Y, Hughes DP. Driven to death: inhibition of farnesylation increases Ras activity in osteosarcoma and promotes growth arrest and cell death. Mol Cancer Ther 2010; 9: 1111-9.